Table 5. Kaplan-Meier analysis for 5-year overall survival rate.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clinical features | N | 5-year OS | X2 -value | P-value  |
| Censored subjects Events |
| Ages |  |  |  |  |  |
| ≤45 | 76 | 54(71.1%) | 22(28.9%) |  |  |
| >45 | 36 | 23(63.9%) | 13(26.1%) | 0.2197 | 0.6392 |
| Clinical stage |  |  |  |  |  |
|  I, II | 35 | 33(94.3%) | 2(5.7%) |  |  |
|  III，IV | 77 | 44(57.1%) | 33(42.9%) | 14.92 | 0.0001 |
| Molecular subtype |  |  |  |  |  |
|  Luminal A | 57 | 47(82.5%) | 10(17.5%) |  |  |
| Luminal B | 26 | 16(61.5%) | 10(38.5%) |  |  |
| HER-2+ | 12 | 9(75.0%) | 3(25.0%) |  |  |
|  TNBC | 17 | 5(29.4%) | 12(70.6%) | 36.91 | <0.0001 |
| ER |  |  |  |  |  |
| + | 83 | 63(75.9%) | 20(24.1%) |  |  |
| - | 29 | 14(48.3%) | 15(51.7%) | 14.25 | 0.0002 |
| PR |  |  |  |  |  |
| + | 57 | 47(82.5%) | 10(17.5%) |  |  |
| - | 55 | 30(54.5%) | 25(45.5%) | 12.21 | 0.0005 |
| HER2 |  |  |  |  |  |
| + | 28 | 20(71.4%) | 8(28.6%) |  |  |
| - | 84 | 57(67.9%) | 27(32.1%) | 0.1494 | 0.6991 |
| Lymph-node metastasis |  |  |  |  |  |
|  Yes | 45 | 17(37.8%) | 28(62.2%) |  |  |
|  No | 67 | 60(89.6%) | 7(10.4%) | 40.91 | <0.0001 |
| Tumor size |  |  |  |  |  |
| ≤ 2cm | 56 | 42(75.0%) | 14(25.0%) |  |  |
| ＞2cm, ≤ 5cm＞5cm | 4511 | 28(62.2%)7(63.6%) | 17(37.8%)4(36.4%) | 1.979 | 0.3718 |
|  |  |  |  |  |  |
| Mutations in breast cancer tissuesWithout With | 6745 | 56(83.6%)21(46.7%) | 11(16.4%)24(53.3%) | 19.19 | <0.0001 |

BC: breast cancer; P-value <0.05, statistically significant.